Metabolic syndrome and nonalcoholic fatty liver disease. The role of endothelial progenitor cells

被引:9
|
作者
Gutierrez-Grobe, Ylse [1 ]
Gavilanes-Espinar, Juan G. [1 ]
Masso-Rojas, Felipe A. [2 ]
Sanchez-Valle, Vicente [1 ]
Paez-Arenas, Araceli [2 ]
Ponciano-Rodriguez, Guadalupe [3 ]
Chavez-Tapia, Norberto C. [1 ]
Uribe, Misael [1 ]
Mendez-Sanchez, Nahum [1 ]
机构
[1] Med Sur Clin & Fdn, Liver Res Unit, Mexico City 14050, DF, Mexico
[2] Inst Nacl Cardiol Ignacio Chavez, Dept Physiol, Mexico City, DF, Mexico
[3] Univ Nacl Autonoma Mexico, Fac Med, Dept Publ Hlth Invest, Mexico City 04510, DF, Mexico
关键词
Endothelial progenitor cells; Cardiovascular risk; NAFLD; Metabolic syndrome; Endothelium; CARDIOVASCULAR-DISEASE; RISK; HEART; PATHOGENESIS; MORTALITY;
D O I
10.1016/S1665-2681(19)31296-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background. Endothelial dysfunction has been previously described in metabolic syndrome patients. The levels of circulating endothelial progenitor cells (EPCs) inversely correlates with the incidence of cardiovascular disease. The aim of this study was to investigate the association between NAFLD, metabolic syndrome and EPC levels. Material and methods. A cross-sectional pilot study was performed at a university hospital in Mexico. Two groups of patients without previously known chronic diseases were studied and classified according to the presence of NAFLD. Anthropometric, dietary, and biochemical variables, and circulating EPC number were measured and compared between the groups. Results. Forty subjects were included and classified into two groups: patients with NAFLD (n = 20) and a control group (n = 20). The overall prevalence of insulin resistance and metabolic syndrome was 25% and 17.5%, respectively. EPC levels were found to be higher in the NAFLD group (p < 0.05) as in the patients with insulin resistance (p < 0.01) and metabolic syndrome (p < 0.01). These levels showed correlation with the severity of steatosis. Conclusions. Patients with NAFLD have increased levels of EPC, such levels are associated with the severity of NAFLD. These findings may suggest that these cells may play a role in the early natural history of NAFLD. EPC might be increased in an attempt to repair the endothelial damage resulting from metabolic alterations accompanying NAFLD. Further studies are needed to establish the dynamics of these cells in NAFLD.
引用
收藏
页码:908 / 914
页数:7
相关论文
共 50 条
  • [41] Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome
    Miele, Luca
    Gasbarrini, Giovanni
    Giorgio, Valentina
    Gasbarrini, Antonio
    Grieco, Antonio
    INTERNAL AND EMERGENCY MEDICINE, 2016, 11 (01) : 3 - 10
  • [42] Lipid profiles in nonalcoholic fatty liver disease.
    Adams, LA
    Keach, J
    Lindor, KD
    Angulo, P
    HEPATOLOGY, 2003, 38 (04) : 512A - 512A
  • [43] Complex impacts of gallstone disease on metabolic syndrome and nonalcoholic fatty liver disease
    Lyu, Jingting
    Lin, Qinghong
    Fang, Zhongbiao
    Xu, Zeling
    Liu, Zhengtao
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [44] Preclinical cardiac disease in nonalcoholic fatty liver disease with and without metabolic syndrome
    Makker, Jasbir
    Tang, Hassan
    Bella, Jonathan N.
    Kumar, Kishore
    Chime, Chukwunonso
    Patel, Harish
    Kamal, Muhammad Umar
    Shaikh, Danial
    Vootla, Vamshidhar
    Bajantri, Bharat
    Gomceli, Umut
    Alshelleh, Mohammad
    Peralta, Richard
    Zhang, Aiyi
    Chilimuri, Sridhar
    AMERICAN JOURNAL OF CARDIOVASCULAR DISEASE, 2019, 9 (05): : 65 - 77
  • [45] Nonalcoholic Fatty Liver Disease as a Contributor to Hypercoagulation and Thrombophilia in the Metabolic Syndrome
    Targher, Giovanni
    Chonchol, Michel
    Miele, Luca
    Zoppini, Giacomo
    Pichiri, Isabella
    Muggeo, Michele
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2009, 35 (03): : 277 - 287
  • [46] Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: Clinical Implications and Treatment
    Rahimi, Robert S.
    Landaverde, Carmen
    NUTRITION IN CLINICAL PRACTICE, 2013, 28 (01) : 40 - 51
  • [47] Pediatric nonalcoholic fatty liver disease,metabolic syndrome and cardiovascular risk
    Lucia Pacifico
    Valerio Nobili
    Caterina Anania
    Paola Verdecchia
    Claudio Chiesa
    World Journal of Gastroenterology, 2011, 17 (26) : 3082 - 3091
  • [48] Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk
    Pacifico, Lucia
    Nobili, Valerio
    Anania, Caterina
    Verdecchia, Paola
    Chiesa, Claudio
    WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (26) : 3082 - 3091
  • [49] Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation Metabolic Syndrome?
    Katsiki, Niki
    Perez-Martinez, Pablo
    Anagnostis, Panagiotis
    Mikhailidis, Dimitri P.
    Karagiannis, Asterios
    CURRENT VASCULAR PHARMACOLOGY, 2018, 16 (03) : 219 - 227
  • [50] Risk factors of the metabolic syndrome in patients with nonalcoholic fatty liver disease
    Uzcategui, Lilia R.
    Gegorio Angel, Jose
    Martinez, Dasyl
    Gomez-Perez, Roald
    Arata-Bellabarba, G.
    MEDULA, 2008, 17 (01): : 7 - 14